A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)
      QxMD      Google Scholar   
Citation:
J Thorac Oncol vol 5 (3) 380-384
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
524  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA032291, CA33601, CA77597, CA11789, U10 CA077658, CA77406, CA35113, CA32291, U10 CA086726, CA41287, U10 CA035279, U10 CA045808, CA03927, U10 CA031946, U10 CA033601, U10 CA077597, CA45808, CA35279, U10 CA114558, U10 CA045418, CA86726, U10 CA041287, U10 CA035113, U10 CA031946-28, CA114558-02, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31983, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                 
Networks:
 
Study
CALGB-30602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Phase II, Dasatinib, Small cell lung cancer